Here we determined the important role of RARγ agonist treatment on the reduction of proteoglycan in the osteochondroma explant culture as characterized by alcian blue staining, and strongly stimulated proteoglycan degradation as determined by the immunostaining of the neoepitope of aggrecan core proteins. This evidence concerns the gene ACAN and Osteochondroma.